Oxford BioDynamics PLC (LMQ.F)
| Previous close | 0.0630 |
| Open | 0.0625 |
| Bid | 0.0625 x N/A |
| Ask | 0.1470 x N/A |
| Day's range | 0.0625 - 0.0625 |
| 52-week range | 0.0450 - 0.5300 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Bupa UK to cover EpiSwitch® CiRT for customers with cancer
OXFORD, England, October 18, 2023--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform and Bupa, the UK’s leading health insurer, announce a strategic agreement to give Bupa patients access to OBD’s EpiSwitch CiRT (Checkpoint inhibitor Response Test).
- Business Wire
Oxford BioDynamics Receives Reimbursement Code for EpiSwitch® Prostate Screening (PSE) Test
OXFORD, England, October 03, 2023--Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch 3D genomics platform, confirms the assignment and publication of a Proprietary Laboratory Analysis Code (PLA Code) by the American Medical Association’s CPT (Current Procedural Terminology) Editorial Board (https://www.ama-assn.org/practice-management/cpt/cpt-pla-codes).
- Business Wire
Oxford Biodynamics Announces US Launch of its 94% Accurate EpiSwitch® Prostate Screening Blood Test to Men With Prostate Cancer Risk
OXFORD, England, September 26, 2023--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, today announced validation of its EpiSwitch Prostate Screening (PSE) blood test in its US clinical laboratory, resulting in the immediate access to its highly accurate PSE test to men with prostate cancer risk.
